

William Herrington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11952740/publications.pdf>

Version: 2024-02-01

21
papers

2,952
citations

623734
14
h-index

752698
20
g-index

21
all docs

21
docs citations

21
times ranked

4364
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, The, 2011, 377, 2181-2192.	13.7	2,087
2	Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes and Endocrinology, the, 2016, 4, 829-839.	11.4	234
3	Diabetes and Cause-Specific Mortality in Mexico City. New England Journal of Medicine, 2016, 375, 1961-1971.	27.0	207
4	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	1.8	82
5	Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysis, 2015, 28, 35-47.	1.3	49
6	Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD. American Journal of Kidney Diseases, 2016, 67, 31-39.	1.9	42
7	Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International, 2018, 93, 1000-1007.	5.2	32
8	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	2.7	30
9	Neutrophil gelatinase-associated lipocalin in kidney transplantation: A review. Transplantation Reviews, 2015, 29, 139-144.	2.9	27
10	Impact of CKD on Household Income. Kidney International Reports, 2018, 3, 610-618.	0.8	25
11	Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1794-1801.	4.5	22
12	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	2.9	21
13	The Effect of Lowering LDL Cholesterol on Vascular Access Patency. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 914-919.	4.5	19
14	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
15	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial-Adjudicated Direct Follow-up Data in the UK. JAMA Network Open, 2021, 4, e2139748.	5.9	15
16	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
17	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology: JASN, 2022, 33, 291-303.	6.1	10
18	Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150,000 Mexican adults. European Journal of Preventive Cardiology, 2022, 29, 730-738.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection. Nephrology Dialysis Transplantation, 2018, 33, gfw396.	0.7	6
20	Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study. Journal of Clinical Epidemiology, 2020, 128, 148-156.	5.0	4
21	Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. Clinica Chimica Acta, 2015, 439, 112-114.	1.1	0